Osimertinib for EGFR Mutation Lung Cancer: 56 Real Stories

Stage IV EGFR Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR-positive; T790M-positive

Metastatic Site: Not reported

As of September 2021, Ashley was living with incurable but treatable EGFR-positive/T790M-positive lung cancer on daily osimertinib/Tagrisso with ongoing oncology monitoring and side-effect management.

The Patient StoryRead more →

Cancer Survivor Story: How I Got Diagnosed with Lung Cancer

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: EGFR-positive; T790M mutation

Metastatic Site: Both lungs

As of August 2021, Ashley had been living for almost 4 years with incurable but treatable EGFR-positive T790M non-small cell lung cancer involving many tiny nodules across both lungs.

The Patient StoryRead more →

Facial paralysis from progression of EGFR-positive metastatic lung cancer improved with osimertinib

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: EGFR exon 21 p.Leu858Arg mutation.

Metastatic Site: brain; leptomeninges and facial nerves

Osimertinib rapidly resolved the bilateral facial weakness and reduced the brain lesions, but after 15 months seizures recurred and three smaller brain metastases had increased in size.

PubMed CentralRead more →

Stage IV EGFR-mutated lung cancer responding to osimertinib despite new lung opacities

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; EGFR T790M mutation

Metastatic Site: bilateral lungs

Over the following year on osimertinib, imaging showed an excellent tumour response with gradual improvement of the lung opacities and sustained clinical improvement.

PubMed CentralRead more →

Osimertinib rechallenge after severe pneumonitis in Stage IV lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, liver, bone, leptomeninges

She initially regained a significant response after osimertinib rechallenge without recurrent pneumonitis, but developed progressive leptomeningeal disease after 11 months.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ginger's Patient Story

Patient Info: Ginger Tam, Female | Stage IV

Biomarkers: EGFR mutation

Ginger lived for more than 5 years with metastatic lung cancer while receiving multiple research-driven treatments. She died on February 10, 2018.

EGFR-Mutated Stage IV Lung Adenocarcinoma With Painful Finger Lesions During Osimertinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR-mutated; EGFR T790M-positive at relapse

She remained on active osimertinib treatment; the finger lesions persisted but were controlled with colloidal oatmeal.

PubMed CentralRead more →

EGFR-mutated NSCLC on Tarceva with CT follow-up pending and future resistance options discussed

Patient Info: Anonymized, Male

Biomarkers: EGFR mutation; T790M resistance discussed as a possible future resistance mechanism

As of December 2015, he was on Tarceva/erlotinib for EGFR-mutated NSCLC, had new cough/chest pain/fatigue, and was waiting for a control CT to clarify whether the tumor remained controlled.